Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
1
17%
Ph phase_4
1
17%
Ph phase_1
1
17%
Ph phase_3
2
33%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 32 (33.3%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

terminated117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completednot_applicable

Besifloxacin in Bacterial Keratitis

NCT02497365
completedphase_4

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

NCT01296191
completedphase_3

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

NCT00348348
terminatedphase_3

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

NCT01740388
completedphase_2

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

NCT00972777
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02497365Not Applicable

Besifloxacin in Bacterial Keratitis

Completed
NCT01296191Phase 4

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Completed
NCT00348348Phase 3

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

Completed
NCT01740388Phase 3

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Terminated
NCT00972777Phase 2

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Completed
NCT00905762Phase 1

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6